Leucine-rich repeat kinase 2 (LRRK2)
Leucine-rich repeat kinase 2 (LRRK2) belongs to the ROCO protein family, a class of multi-domain proteins characterized by the presence of a 200-250 amino acid Ras of Complex protein (Roc) domain, immediately followed by a 300-400 amino acid domain termed C-terminal of Roc (COR)1. The function of LRRK2 is not well known although it has been identified as a tyrosine kinase-like protein, with the Roc domain able to bind guanosine triphosphate (GTP)2.
Multiple lines of evidence have suggested that LRRK2 is a crucial factor in understanding the etiology of Parkinson’s disease (PD). Among all the causative genes, mutations in LRRK2 have been proved to associate with autosomal dominant PD alongside a-synuclein mutations3. Mutations that activate LRRK2 predispose to PD, which could suggest that LRRK2 inhibitors could have therapeutic benefit4.
While LRRK2 is the focus of intensive research in the Parkinson's field, a lack of high-quality LRRK2 antibodies has been a major roadblock in the successful development of LRRK2-based therapies. To bring the tools you need for Parkinson’s disease research, we partnered with The Michael J. Fox Foundation (MJFF) to develop unique and high quality LRRK2 rabbit monoclonal antibodies and make them available to the wider research community.
Applications
Our range of products to LRRK2 are validated for use in key applications including western blot, immunocytochemistry, immunohistochemistry, and immunoprecipitation.
 | Lane 1: A549 whole cell lysate (20 µg) Lane 2: MEF whole cell lysate (20 µg) Lane 3: A549 (KO) whole cell lysate (20 µg) Lane 4: MEF (KO) whole cell lysate (20 µg) Lanes 1 - 4: Merged signal (red and green). Green - ab133475 observed at 286 kDa. Red - loading control, ab18058, observed at 130 kDa. ab133475 was shown to specifically react with Wild type A549 and MEF cells whilst no band was observed when knockout samples were used. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and knockout samples were subjected to SDS-PAGE. Ab133475 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging. |
| Western blot - Anti-LRRK2 antibody [MJFF3 (c69-6)] (ab133475) | |
 | ab133474 staining LRRK2 in Neuro-2a (mouse neuroblastoma cell line) cell line by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody (1/500). ab150077 was used as the secondary antibody (1/1000). Tubulin stained using ab7291 (1/1000) and ab150120 (1/1000) as the secondary. Nuclear counter stained with DAPI. |
| Immunocytochemistry/ Immunofluorescence - Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) |
Product recommendations for your LRRK2 research
| Anti-LRRK2 antibodies | Applications | Species reactivity |
| Recombinant Anti-LRRK2 antibody [MJFF2 (c41-2)] (ab133474) | ICC/IF, IHC-P, WB, IP, IHC-FrFl | Mouse, Rat, Human |
| Recombinant Anti-LRRK2 antibody [MJFF3 (c69-6)] (ab133475) | IP, ICC/IF, IHC-P, WB | Mouse, Rat, Human |
| Recombinant Anti-LRRK2 antibody [MJFF4 (c81-8)] (ab133476) | WB, IHC-P, ICC/IF, IP | Mouse, Rat, Human |
| Recombinant Anti-LRRK2 antibody [MJFF2 (c41-2)] (Alexa Fluor® 647) (ab195023) | ICC/IF | Mouse, Rat, Human |
| Recombinant Anti-LRRK2 (phospho S935) antibody [UDD2 10(12)] (ab133450) | WB | Mouse, Human |
| Recombinant Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) | WB | Human |
| Recombinant Anti-LRRK2 (phospho S955) antibody [MJF-R11 (75-1)] (ab169521) | WB | Mouse, Human |
| KO Cell lines | ||
| Human LRRK2 knockout HeLa cell line (ab255405) | ||
| Protein | Applications | |
| Recombinant human LRRK2 protein (ab177261) | Functional studies, SDS-PAGE |
View our full range of products to LRRK2.
References
- Gandhi P.N., Chen S.G., Wilson-Delfosse A.L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res. 87(6):1283–1295. (2009)
- Bekris L.M., Mata, I.F., Zabetian, C.P. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 23(4) pages 228–242. (2010)
- Li, J.Q, Tan, L. and Yu, J.T. The role of the LRRK2 gene in Parkinsonism Molecular Neurodegeneration 9 Article number: 47 (2014)
- Lis P., Burel S., Steger M., et al. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochem J. 475(1) pages 1–22. (2018)